Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes

This study has been completed.
Sponsor:
Collaborators:
Juvenile Diabetes Research Foundation
Amylin Pharmaceuticals, LLC.
Merck Sharp & Dohme Corp.
Pfizer
Eli Lilly and Company
Takeda
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Novartis
Information provided by (Responsible Party):
Foundation for the National Institutes of Health
ClinicalTrials.gov Identifier:
NCT01663207
First received: August 9, 2012
Last updated: July 14, 2014
Last verified: August 2012

August 9, 2012
July 14, 2014
May 2012
April 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01663207 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes
Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes

A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.

A three-year observational study to standardize the meal tolerance and maximum stimulational tests for measuring beta cell function in the clinical setting. It also aims to improve methods for the early prediction of the long-term response to an intervention and for identification of patients at risk for rapid beta cell function deterioration, thereby enabling future clinical studies that examine diabetes progression.

Observational
Observational Model: Case-Crossover
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

obese individuals with prediabetes

Type 2 Diabetes
Not Provided
obese individuals with prediabetes
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Ability to give informed consent and comply with all study requirements
  2. Overweight and obese, generally healthy men and women. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history (with the exception of glucose tolerance, see below), full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
  3. Glucose Parameters:

    1. Fasting plasma glucose ≥100 mg/dL and <126 mg/dL
    2. 2h post-OGTT glucose of ≥140 and <200 mg/dL
    3. HbA1c<6.5%
  4. Women of child-bearing potential are allowed (but must agree to use non-hormonal contraception and not plan to become pregnant for the duration of the study). Must agree to maintain the same contraceptive measures throughout the study. Acceptable contraceptive methods for female subjects of childbearing potential include one of the following:

    • Abstinence.
    • One (1) of the following methods:

      • Tubal ligation
      • Copper-containing intrauterine device (IUD)
      • Condom AND spermicidal foam/gel/film/cream/suppository
      • Male partner who has had a vasectomy for at least 6 months.
  5. It is required that all male subjects use an acceptable method of contraception (as outlined below), starting from the first dose of study medication and continuing for at least 28 days after the last dose of study drug:

    1. Abstinence
    2. A condom AND one of the following:

      • Vasectomy for more than 6 months.
      • Female partner who meets one of the following conditions:

        • Has had a tubal ligation, hysterectomy, or bilateral oophorectomy; or
        • Is post menopausal (menopause is defined as over the age of 60 years, or between 45 and 60 years being amenorrheic for at least 2 years with plasma (FSH) level > 30 UI/L) or
        • Or for female partners of the male participants, in addition to hysterectomy, oophorectorectomy, or post-menopausal status, that the use of a spermicidal gel or foam will constitute adequate protection in conjunction with use of a condom by the male.
  6. BMI 27-40; stable weight (less than 3% change in past 3 months) Age Range: 30-65
  7. No history of diabetes mellitus
  8. Other conditions may be allowed, if medically stable and controlled for at least four weeks within acceptable limits, including: hypertension, dyslipidemia, osteoarthritis, osteoporosis
  9. Smokers allowed, but must be able to participate on inpatient stay and not smoke

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, neoplastic, or allergic or clinical findings at Screening (seasonal allergies OK).
  2. Any condition possibly affecting absorption (eg, gastrectomy, malabsorption syndromes, abdominal surgery other than appendectomy, cholecystectomy or hysterectomy).
  3. Use of unacceptable medications
  4. A positive urine drug screen.
  5. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
  6. Treatment with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication.
  7. 12 lead ECG demonstrating QTc >450 msec at Screening for males, 470 msec for females. If QTc exceeds 450/470 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility. An ECG with evidence for possible old myocardial infarction will need to have prior ECGs to document stability of finding.
  8. Supine blood pressure >=140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single measurement. If elevated, confirm by a single repeat, following at least 10 minutes of rest.
  9. Screening serum alanine transaminase (ALT) or serum aspartate transaminase (AST) greater than 2X the upper limit of the laboratory reference range.
  10. Elevated fasting triglycerides at screening (>500 mg/dL), confirmed by a single repeat if deemed necessary.
  11. Pregnant or nursing females; inability to use effective contraception.
  12. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
  13. Participation in a clinical biomedical research study within prior two months may be excluded, depending on study type and details.
  14. History of sensitivity to heparin or heparin-induced thrombocytopenia, if utilized by the site for blood draws.
  15. Unwilling or unable to comply with directions and procedures described in this protocol.
  16. Subject is the Investigator or a sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or a relative of study personnel directly involved with the conduct of the study.
  17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Both
30 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01663207
Beta Cell - Protocol 1c
No
Foundation for the National Institutes of Health
Foundation for the National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Juvenile Diabetes Research Foundation
  • Amylin Pharmaceuticals, LLC.
  • Merck Sharp & Dohme Corp.
  • Pfizer
  • Eli Lilly and Company
  • Takeda
  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  • Novartis
Principal Investigator: George Atiee, MD ICON Development Solutions
Foundation for the National Institutes of Health
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP